Akt/Protein Kinase B Inhibitors Analysis, Clinical Trials and Developments

Akt/PKB inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates by Pharma Proff.

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; less risk of systemic infections; and has inexpensive nature. Akt inhibitors through oral route of administration have shown positive results in the clinical studies.

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.

Inquiry Before Purchase this report at: https://www.pharmaproff.com/enquiry/1154

It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of Akt/PKB inhibitors. These technologies are helpful in the development of specific and more effective targeted therapies. For instance, Denovo Biopharma LLC has developed a technology to design new clinical trials for the failed drug candidates due to their undesirable adverse effects. The technology is enabling the drug candidate to be used in lower dose for small and targeted patient population. The key objective of this technology is to identify novel biomarkers by scanning human genome to design a specific study for targeted population.

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

Read More

Increasing Geriatric Population Resulting in Clinical Decision Support System (CDSS) Market Advance

The rising demand for advanced healthcare services and remote patient monitoring systems, investments by healthcare information technology (HIT) firms, and support from government organizations are driving the adoption of clinical decision support system (CDSS). From $410.5 million in 2015, the CDSS market is projected to grow at a CAGR of 21.5% during 2016–2022. CDSS is an HIT system, which helps doctors and other medical professionals with clinical decision making, thereby improving the quality of healthcare and patient outcomes.

To learn more about this report@ http://bit.ly/37XTcec

Of the two types of solutions available — integrated and standalone — integrated solutions dominated the CDSS market during the historical period (2012–2015). Such solutions are also expected to witness the higher CAGR, of 22.4%, during the forecast period, as these are integrated with electronic health records (EHR) and computerized physician order entry (CPOE) systems, especially those that relate to drug allergy alerts, drug–drug interactions, and clinical reminders. As integrated systems help prevent medication errors, the demand for these is growing.

The increasing support for the technology from governments is also helping the market grow. For instance, under the Connecting Europe Facility, the European Union granted around $18.1 million for deploying digital service infrastructures (DSI) in the eProcurement, eHealth, online dispute resolution (ODR), and eIdentification (eID) areas. Similarly, the U.S. government has implemented the Health Information Technology for Economic and Clinical Health (HITECH) Act, which mandates the use of digital health technologies.

During the historical period, North America held the largest share in the CDSS market, in terms of value, and the same scenario is expected during the forecast period. This would be a result of the advanced healthcare infrastructure, growing geriatric population, increasing healthcare spending, and rising incidence of chronic and lifestyle-associated diseases here. As per the American Diabetes Association, the number of diabetes patients in the U.S. rose from 25.8 million in 2010 to about 29.1 million in 2012.

Therefore, with the increase in the geriatric population, which is more prone to chronic diseases and also unable to visit hospitals regularly, the demand for clinical decision support systems will continue rising.

Read More